Lv1
40 积分 2023-06-12 加入
Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study
4天前
已完结
First and Second-line Treatments in Metastatic Renal Cell Carcinoma
4天前
已完结
Safety and Efficacy of Second-Line TKI Plus Anti-PD1 in Metastatic Non-Clear Cell Renal Cell Carcinoma: A Real-World Study
4天前
已完结
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma
4天前
已关闭
Asundexian versus Apixaban in Patients with Atrial Fibrillation
13天前
已完结
Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma: The Hovon 143 Study
1个月前
已完结
Evidence-based mechanisms of synergy with IMiD agent-based combinations in multiple myeloma
1个月前
已完结
Autologous transplantation of P63+ lung progenitor cells for chronic obstructive pulmonary disease therapy
1个月前
已完结
Ruxolitinib combined with prednisone, thalidomide and danazol in patients with myelofibrosis: Results of a pilot study
1个月前
已完结
Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case example
1个月前
已完结
皖公网安备34019202002308
